Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2701 - 2800
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2701 | 26659056 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2702 | 26659068 |
US |
1 | |
Hospitalisation, Dermatitis atopic, Dermatitis contact, |
||||
DUPILUMAB, |
||||
| 2703 | 26659079 |
US |
31 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2704 | 26659085 |
US |
25 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2705 | 26659093 |
US |
31 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2706 | 26659448 |
US |
57 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2707 | 26659453 |
US |
8 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2708 | 26659454 |
US |
8 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2709 | 26659520 |
US |
2 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2710 | 26659533 |
US |
16 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2711 | 26659535 |
US |
51 | 2 |
Dermatitis atopic, Skin swelling, Skin discolouration, Pruritus, Skin fissures, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 2712 | 26659540 |
US |
28 | 2 |
Dermatitis atopic, Eczema, Rash, |
||||
DUPILUMAB, |
||||
| 2713 | 26659545 |
US |
18 | 2 |
Dizziness, Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2714 | 26659548 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2715 | 26659652 |
US |
2 | |
Nausea, Urticaria, Dermatitis atopic, |
||||
DUPILUMAB, LORATADINE, LORATADINE ORAL, |
||||
| 2716 | 26659721 |
US |
39 | 1 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2717 | 26661626 |
US |
64 | 2 |
Diarrhoea, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2718 | 26663758 |
US |
||
Flatulence, Diarrhoea, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2719 | 26664253 |
US |
46 | 2 |
Dermatitis atopic, Drug hypersensitivity, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2720 | 26665679 |
US |
49 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 2721 | 26665843 |
US |
78 | 1 |
Dermatitis atopic, Incorrect dose administered, |
||||
LEBRIKIZUMAB-LBKZ, LEBRIKIZUMAB-LBKZ, |
||||
| 2722 | 26665854 |
US |
12 | |
Skin discolouration, Condition aggravated, Pruritus, Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 2723 | 26652492 |
US |
2 | |
Dermatitis atopic, Drug ineffective, Incorrect route of product administration, |
||||
LEBRIKIZUMAB-LBKZ, LEBRIKIZUMAB-LBKZ, LEBRIKIZUMAB-LBKZ, |
||||
| 2724 | 26652614 |
US |
17 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 2725 | 26653380 |
78 | ||
Wound infection staphylococcal, Wound infection pseudomonas, Xerosis, Wound, Dermatitis atopic, Skin fissures, |
||||
ACITRETIN, VITAMIN C, ERGOCALCIFEROL, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, COPPER, CUPRIC CHLORIDE, NICOTINAMIDE, IMIQUIMOD, CALCIPOTRIENE, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, ZINC OXIDE, PACIFICA ULTRA CC CREAM RADIANT FOUNDATION SPF 30 WARM/LIGHT, ZINC OXIDE OINTMENT, PACIFICA ULTRA CC CREAM RADIANT FOUNDATION SPF 30 WARM/TAN, ZINC OXIDE 20%, SKIN PROTECTANT, PACIFICA ULTRA CC CREAM RADIANT FOUNDATION SPF 30 NATURAL/MEDIUM, PACIFICA ULTRA CC CREAM RADIANT FOUNDATION SPF 30 COOL/DEEP, MINERAL SUNSHIELD UNIVERSAL TINT BROAD SPECTRUM SPF 30 SUNSCREEN, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 2726 | 26653764 |
US |
62 | 2 |
Glaucoma, Injection site bruising, Dermatitis atopic, Stress, Knee arthroplasty, |
||||
DUPILUMAB, |
||||
| 2727 | 26653790 |
US |
50 | 2 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2728 | 26653793 |
US |
36 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2729 | 26653844 |
US |
78 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2730 | 26653845 |
US |
24 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2731 | 26653859 |
US |
2 | |
Dermatitis atopic, Device use issue, |
||||
DUPILUMAB, CRISABOROLE, |
||||
| 2732 | 26653865 |
US |
10 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Injection site pain, |
||||
DUPILUMAB, |
||||
| 2733 | 26653867 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, BIOTIN, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CHLORTHALIDONE, DOCUSATE SODIUM, EPINEPHRINE, ADRENALINUM, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, MAGNESIUM, OLOPATADINE, EVOLOCUMAB, RISEDRONATE SODIUM, TRETINOIN, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VITAMIN C, ERGOCALCIFEROL, |
||||
| 2734 | 26653872 |
US |
73 | 2 |
Eczema, Eye pruritus, Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2735 | 26653886 |
US |
4 | 2 |
Dermatitis atopic, Rash, Sensitivity to weather change, |
||||
DUPILUMAB, |
||||
| 2736 | 26653950 |
US |
42 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2737 | 26653962 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2738 | 26654032 |
US |
81 | 2 |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, |
||||
| 2739 | 26654078 |
US |
||
Pneumonia, Respiratory syncytial virus infection, Cardiac failure congestive, Eye disorder, Pruritus, Dermatitis atopic, Device malfunction, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 2740 | 26654155 |
US |
73 | 2 |
Cardiac operation, Rash, Product dose omission issue, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2741 | 26654245 |
US |
66 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2742 | 26654500 |
2 | ||
Weight gain poor, Pathologic myopia, Microphthalmos, Retinopathy of prematurity, Developmental hip dysplasia, Joint dislocation, Blepharophimosis congenital, Pulmonary hypertensive crisis, Congenital central nervous system anomaly, Intraventricular haemorrhage neonatal, Dermatitis exfoliative generalised, Cerebellar atrophy, Periventricular leukomalacia, Seizure, Hyponatraemia, Dermatitis atopic, Abdominal hernia, Cortisol decreased, White matter lesion, Streptococcal infection, Seborrhoeic dermatitis, Cerebral ventricle dilatation, Staphylococcal skin infection, Obstructive sleep apnoea syndrome, |
||||
NITRIC OXIDE, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DOBUTAMINE, |
||||
| 2743 | 26654730 |
US |
81 | 2 |
Erythema, Dizziness, Balance disorder, Vertigo, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2744 | 26654795 |
US |
||
Dermatitis atopic, |
||||
RUXOLITINIB, DUPILUMAB, |
||||
| 2745 | 26654874 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2746 | 26654901 |
US |
90 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, AMLODIPINE BESYLATE, BUSPIRONE HYDROCHLORIDE, CARVEDILOL, DONEPEZIL HYDROCHLORIDE, ESCITALOPRAM OXALATE, ESCITALOPRAM, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LEVETIRACETAM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 2747 | 26655102 |
US |
51 | 1 |
Psoriatic arthropathy, Arthropathy, Dermatitis atopic, Dermatitis, Pain of skin, Skin lesion, Pruritus, Skin haemorrhage, Poor quality sleep, Malaise, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, ABATACEPT, |
||||
| 2748 | 26655132 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, ERGOCALCIFEROL, AMLODIPINE BESYLATE, PHENAZOPYRIDINE HYDROCHLORIDE, GABAPENTIN, |
||||
| 2749 | 26655303 |
US |
7 | 2 |
Pruritus, Dermatitis atopic, Therapeutic response shortened, Illness, Nasopharyngitis, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, EPINEPHRINE, ADRENALINUM, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 2750 | 26655333 |
US |
1 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 2751 | 26655404 |
US |
2 | |
Dermatitis atopic, Papule, |
||||
DUPILUMAB, TIRZEPATIDE, TOPIRAMATE, LORATADINE, LORATADINE TABLET, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, RUXOLITINIB, SUMATRIPTAN SUCCINATE, |
||||
| 2752 | 26655418 |
US |
1 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2753 | 26655424 |
US |
30 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Skin exfoliation, Skin fissures, |
||||
DUPILUMAB, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 2754 | 26646157 |
US |
60 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2755 | 26646994 |
IL |
41 | 2 |
Loss of consciousness, Constipation, Asthenia, Diarrhoea, Ocular hyperaemia, Injection site haematoma, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2756 | 26647670 |
US |
31 | 2 |
Crohn^s disease, Dermatitis atopic, Pruritus, Skin exfoliation, Dry skin, |
||||
DUPILUMAB, |
||||
| 2757 | 26648317 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2758 | 26648321 |
US |
40 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2759 | 26648437 |
US |
21 | 1 |
Peripheral swelling, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2760 | 26648453 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2761 | 26648462 |
US |
82 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 2762 | 26648516 |
US |
74 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2763 | 26648522 |
US |
2 | |
Back pain, Arthralgia, Dermatitis atopic, Product dose omission issue, Therapeutic response shortened, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, CALCIUM, LEVOCETIRIZINE DIHYDROCHLORIDE, LOSARTAN POTASSIUM, LOSARTAN, PROPRANOLOL HYDROCHLORIDE, |
||||
| 2764 | 26648525 |
US |
18 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2765 | 26648532 |
US |
11 | 2 |
Dermatitis atopic, Rash, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 2766 | 26648544 |
US |
49 | 2 |
Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2767 | 26648545 |
US |
7 | 2 |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 2768 | 26648580 |
US |
28 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2769 | 26648596 |
US |
63 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2770 | 26648598 |
US |
1 | 1 |
Cough, Nasopharyngitis, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2771 | 26648599 |
US |
77 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2772 | 26648607 |
US |
2 | |
Wheezing, Depressed mood, Pigmentation disorder, Dermatitis atopic, |
||||
DUPILUMAB, ALBUTEROL SULFATE, CYCLOBENZAPRINE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, PREDNISONE, ERGOCALCIFEROL, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 2773 | 26648609 |
US |
3 | 1 |
COVID-19, Influenza, Immune system disorder, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2774 | 26648661 |
US |
2 | |
Discomfort, Rash, Product dose omission issue, Dermatitis atopic, |
||||
DUPILUMAB, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, BUPROPION, BUPROPION HYDROCHLORIDE, |
||||
| 2775 | 26648748 |
US |
18 | 2 |
Dermatitis atopic, Rash, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2776 | 26648752 |
US |
2 | |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 2777 | 26648765 |
US |
1 | |
Dermatitis atopic, Haemorrhage, |
||||
DUPILUMAB, |
||||
| 2778 | 26648773 |
US |
29 | 2 |
Dry skin, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2779 | 26648780 |
US |
68 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2780 | 26648795 |
US |
10 | 2 |
Dermatitis atopic, Eyelid exfoliation, |
||||
DUPILUMAB, |
||||
| 2781 | 26648824 |
US |
21 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2782 | 26648851 |
US |
60 | 1 |
Dermatitis atopic, Skin fissures, Dry skin, Pruritus, Product dose omission issue, Rash, |
||||
DUPILUMAB, |
||||
| 2783 | 26648862 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2784 | 26648911 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2785 | 26648921 |
US |
||
Dermatitis atopic, Incorrect dose administered, Device defective, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 2786 | 26648955 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2787 | 26648962 |
US |
61 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2788 | 26648974 |
US |
70 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2789 | 26648976 |
US |
49 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2790 | 26649174 |
US |
41 | 1 |
Dermatitis atopic, Rash, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 2791 | 26649265 |
US |
23 | 2 |
Eczema, Rash, Discomfort, Sleep disorder, Fatigue, Headache, Upper respiratory tract infection, Nasal congestion, Eye irritation, Mouth injury, Eczema, Swelling of nose, Dyspnoea, Urticaria, Asthma, Impaired quality of life, Nasal congestion, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, NEMOLIZUMAB-ILTO, OMALIZUMAB, |
||||
| 2792 | 26650020 |
US |
58 | 2 |
Neoplasm malignant, Pruritus, Psoriasis, Fungal infection, Eczema, Skin irritation, Pain of skin, Skin weeping, Skin exfoliation, Dry skin, Sleep disorder due to a general medical condition, Skin haemorrhage, Rash, Dermatitis atopic, Pain, Pruritus, Taste disorder, |
||||
DUPILUMAB, DAPAGLIFLOZIN, ANASTROZOLE, ANASTROZOLE TABLETS, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AZELASTINE HYDROCHLORIDE, AZELASTINE, CALCIUM, CALCIUM, ECONAZOLE NITRATE, IPRATROPIUM BROMIDE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, MUPIROCIN, MUPIROCIN CALCIUM, NEBIVOLOL, NEBIVOLOL HYDROCHLORIDE, OLMESARTAN MEDOXOMIL, OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ONDANSETRON HYDROCHLORIDE, PREDNISONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ERGOCALCIFEROL, ROFLUMILAST, NYSTATIN, NYSTATIN OINTMENT, NYSTATIN CREAM, |
||||
| 2793 | 26650412 |
US |
92 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, DOCUSATE SODIUM, CYANOCOBALAMIN, RALOXIFENE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, POLYETHYLENE GLYCOL 3350, MUPIROCIN, MUPIROCIN CALCIUM, GABAPENTIN, LEVOTHYROXINE SODIUM, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 2794 | 26641067 |
CN |
6 | 2 |
Pneumonia chlamydial, Pyrexia, Cough, Dermatitis atopic, Intentional dose omission, Off label use, Therapeutic response decreased, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, CRISABOROLE, |
||||
| 2795 | 26641146 |
US |
45 | 2 |
Major depression, Dermatitis atopic, Asthma, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2796 | 26641153 |
US |
55 | 2 |
Mast cell activation syndrome, Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2797 | 26641487 |
US |
8 | 2 |
Dermatitis atopic, Dry skin, Skin irritation, Pruritus, |
||||
DUPILUMAB, |
||||
| 2798 | 26641551 |
US |
56 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 2799 | 26641557 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2800 | 26641565 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30